SUMMARY Continuous 72-hour infusions of dobutamine reportedly effect sustained clinical improvement in patients with congestive heart failure. This study was designed to determine if shorter, more frequent infusions, delivered in an outpatient setting, elicit a similar response. Twenty-six patients with moderately severe congestive heart failure were randomized, 11 into a control group and 15 into a dobutamine treatment group. Baseline data were collected for 4 weeks in each group. Thereafter, the dobutamine treatment group received 4-hour infusions of dobutamine weekly for 24 weeks. Systolic time intervals, echocardiography, cardiac index and treadmill exercise tolerance were used to follow the progress of the control and dobutamine treatment groups.
SUMMARY Continuous 72-hour infusions of dobutamine reportedly effect sustained clinical improvement in patients with congestive heart failure. This study was designed to determine if shorter, more frequent infusions, delivered in an outpatient setting, elicit a similar response. Twenty-six patients with moderately severe congestive heart failure were randomized, 11 into a control group and 15 into a dobutamine treatment group. Baseline data were collected for 4 weeks in each group. Thereafter, the dobutamine treatment group received 4-hour infusions of dobutamine weekly for 24 weeks. Systolic time intervals, echocardiography, cardiac index and treadmill exercise tolerance were used to follow the progress of the control and dobutamine treatment groups.
The ratio of preejection period to left ventricular ejection time and the cardiac index did not change significantly in either group. The velocity of circumferential fiber shortening and the percent change in the minor axis of the left ventricle during systole improved modestly (p < 0.05) above baseline in the dobutamine group after 14 weeks of treatment and above the corresponding control values (p < 0.05) after 22 weeks. Exercise tolerance (duration) improved 25-51% (all p < 0.05) above baseline in the dobutamine group compared with 10-17% (all p > 0.05 vs baseline) in the control group. Heart rate at maximal exercise did not change significantly from baseline for either group and did not differ significantly between the two groups. Functional classification improved in 12 of 15 dobutamine treatment patients and in only two of 11 control patients (p < 0.05).
In our patients with congestive heart failure, weekly 4-hour dobutamine infusions did not elicit a major change in resting left ventricular function; however, exercise performance and clinical status improved considerably.
A PREVIOUS REPORT from this laboratory indicated that up to 68% of patients with severe congestive heart failure experienced sustained clinical improvement after a 3-day i.v. infusion of dobutamine.1 A follow-up investigation showed that this improvement in clinical status persisted for as long as 10 weeks in more than 40% of these patients and was accompanied by documented improvement of noninvasive indexes of left ventricular function.2 Studies of the histologic and biochemical responses of the failing myocardium to the 3-day infusion of dobutamine showed that mitochondrial morphology and biochemical energetics (ATP, creatine phosphate, cyclic AMP) improved more with dobutamine than with bedrest and saline infusion. [3] [4] [5] We designed the present study to determine whether shorter, more frequent (4-5 hours/week for 24 weeks) i.v. infusions of dobutamine would improve the clinical status and the objective measurements of cardiovascular performance in patients with congestive heart failure. If dobutamine proved to be beneficial, shorter weekly infusions could be given to some of these patients as outpatient therapy.
Methods

Patients
Thirty patients with moderate-to-severe congestive heart failure gave written informed consent and entered the study. Three patients died during the study and one patient who deteriorated clinically was given vasodilator therapy. The data of these four subjects did not extend through the entire period and were withdrawn from analysis. A computer-generated, random-number format was used to randomize the patients into a control group of 11 and a dobutamine treatment group of 15 patients.
The clinical and laboratory features of the patients are presented in table 1. There were no significant differences in the age, sex, diagnoses, functional class, duration of symptoms, degree of cardiomegaly and electrocardiographic findings between the control and dobutamine groups. At entry, two control patients and four dobutamine patients had more than two-pillow orthopnea, five control patients and eight dobutamine patients had pitting pedal edema, and all patients in each group had dyspnea with mild exertion. All patients underwent cardiac catheterization within 3 months before the study; there was no significant difference between the control and dobutamine groups in mean cardiac index (2.06 ± 0.21 and 2.09 ± 0.26 1/min/M2, respectively [± SD]) and left ventricular end-diastolic pressure (23 ± 4 and 24 ± 3 mm Hg, respectively). Four control and five dobutamine patients had mild mitral regurgitation, while two of the controls and three of the dobutamine patients had combined mild mitral and tricuspid regurgitation. To avoid angina-induced dose restriction and the poten- blinded during the treatment period. Clinical evaluation, echocardiography and systolic time intervals were performed every 2 weeks and treadmill exercise testing every 2 months on each subject during the treatment period. A RISA cardiac output was repeated at the end of the treatment period for each group. The patients in the dobutamine treatment group visited the heart failure clinic weekly for the dobutamine infusion; tests were performed before the dobutamine infusion.
The 4-hour dobutamine infusion consisted of dosefinding and maintenance infusions. Patients were given cumulative dose increments of 2.5 ,ug/kg/min over 30 minutes to a maximal dose of 10 1Ag/kg/min or to a dose that increased resting heart rate no more than 40% over the preinfusion heart rate. The infusion was then maintained at this level for 4 .2) . Although the mean resting supine systemic blood pressure was never significantly different between the two groups, the mean systemic pressure of the dobutamine treatment group dropped significantly below baseline after the eighth infusion week ( fig. 2) .
The PEP/LVET did not change from baseline for either group, and there were no differences between any of the corresponding values of the two groups ( fig.  3 ). The %zAD increased modestly above baseline at 18, 22 and 24 weeks in the dobutamine treatment group (fig. 3) ; there were no differences, however, between any corresponding %AD values of the two groups. The dobutamine treatment group experienced a significant increase in mean Vcf values above baseline at 14-24 weeks and above the corresponding values of the control group at 22 and 24 weeks ( fig. 3) . The RISA cardiac index, determined in nine of 11 (fig. 4) . Two of the 11 control group patients improved one furictional class (New York Heart Association) and nine remained unchanged ( fig. 5) . Two of the fifteen dobutamine treatment patients improved two functional classes, 10 improved one functional class, and three remained unchanged. In the control group, seven patients required an increase in diuretic dosage during the study and four required no change. In the dobutamine group, three patients required an increase in diuretic dosage, nine no change and three a decrease. The mean body weight of the control group increased 2.7 kg (71.8 ± 17 to 74.5 ± 20 kg, p = 0.10) from baseline to the end of the treatment period; the mean body weight of the dobutamine group decreased 0.9 kg (72.3 + 15 to 71.4 ± 15 kg, p < 0.10). The frontal heart area in the posteroanterior chest x-ray after treatment was not significantly different from baseline in either group (control 158 i 33 cm2 vs 158 ± 34 cm2; dobutamine 156 ± 33 cm2 vs 155 ± 27 cm2). Although the mechanism of the apparent conditioning effect by the dobutamine infusions is uncertain, the validity of our observations is supported by a study by Liang and colleagues.12 They infused dobutamine, 40 Atg/kg/min, for 2 hours/day for 5 weeks into deconditioned dogs and compared the results with a control group that received a saline infusion and another group that exercised (4 mph, 10°grade) for 2 hours/day for 5 weeks. After 5 weeks, resting heart rate and exercise-provoked increases in heart rate, cardiac output, mean aortic blood pressure, arterial blood lactate, plasma renin activity and norepinephrine concentration decreased significantly for the dobutamine and exercise groups compared with the control group. Their study demonstrates a remarkable similarity between exercise conditioning and intermittent dobutamine infusions in their cardiovascular and metabolic responses. Our patient population was probably deconditioned because of the underlying cardiac disease (concomitant reduction in physical activity). The weekly 4-hour dobutamine infusion reversed some of the deconditioning while minimally altering the resting cardiac-ventricular function status. 
END OF STUDY
It is unlikely that the improved exercise tolerance in the dobutamine group is secondary;to a placebo effect. Exercise duration increased up to 51% in the dobutamine group and only 17% in the control group at the same maximal exercise heart rate. A placebo effect would probably have been accompanied by a higher heart rate response at the higher level of maximal exercise. Ideally, the control group should have received weekly 4-hour saline infusions. A pilot study on the first three patients indicated that a blinded patient could easily distinguish between infusions of saline and dobutamine; this finding in conjunction with our concern for patient compliance blunted our enthusiasm for administering saline for 4 hours every week for 6 months to the control patients.
Exercise conditioning elicits important physiologic and biochemical changes,'3' including decreases in resting heart rate, mean arterial pressure and blood lactate and increases in exercise tolerance and maximal oxygen consumption. Certain mitochondrial enzymes of skeletal muscle also increase with regular exercise. Sympathetic stimulation during exercise may account for some of these changes.17'1 Dobutamine, a synthetic catecholamine, markedly increases ventricular contractility, cardiac output and limb musculoskeletal blood flow;20 at higher doses it elicits tachycardia as well.' These cardiovascular effects are similar to those with exercise; with exercise, these effects are in large part secondary to activation of the sympathetic nervous system. An infusion of dobutamine probably simulates many of the physiologic responses to exercise (e.g., sympathetic nervous system activation, augmentation of blood flow to limb muscle) and as such represents a method of physical conditioning without exercise.
Compared with most other catecholamines, dobutamine has certain advantages in the patient with congestive heart failure.20 It does not change mean systemic blood pressure greatly, it tends to reduce left ventricular filling pressure during the infusion, and it appears to be less arrhythmogenic. When infused in-CIRCULATIONtermittently, other catecholamines may also effect a conditioning response. Norepinephrine is the catecholamine released during exercise. Presumably, its strong vascular a-receptor agonist (vasoconstriction) properties are reversed by the local vascular regulation during exercise, which would not be present during an infusion at rest.
We are not recommending weekly 4-hour catecholamine infusions as a major therapeutic tool for practicing physicians; this treatment may not be practical in many cases. Our intention is to report the phenomenon of drug-induced physical conditioning in deconditioned man with the hope that this concept can be applied to patients with heart failure and other chronic illnesses, immobilized patients and possibly some patients with skeletal myopathies. We suspect that other drugs may also act, in part, through this mechanism.
